Replimune Group, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for REPL, updated each market day.
REPL AI Sentiment
AI sees no strong directional signal for Replimune Group, Inc. stock over the next 10 market days.
Prediction date: July 23, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Replimune Group, Inc.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Sector
Exchange
Market Cap
$799,157,932
Cap Tier
Employees
465
Headquarters
WOBURN, MA
Listed Since
July 20, 2018
Website
REPL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
REPL Volatility
Replimune Group, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
